Despite recent advances in targeted drugs and immunotherapy, cancer remains "the emperor of all maladies" due to inevitable emergence of resistance. Drug resistance is thought to be driven by mutations and/or dynamic plasticity that deregulate pathway activities and regulatory programs of a highly heterogeneous tumour. In this study, we propose a modelling framework to simulate population dynamics of heterogeneous tumour cells with reversible drug resistance. Drug sensitivity of a tumour cell is determined by its internal states, which are demarcated by coordinated activities of multiple interconnected oncogenic pathways. Transitions between cellular states depend on the effects of targeted drugs and regulatory relations between the pathways. Under this framework, we build a simple model to capture drug resistance characteristics of BRAF-mutant melanoma, where two cell states are described by two mutually inhibitory -main and alternative -pathways. We assume that cells with an activated main pathway are proliferative yet sensitive to the BRAF inhibitor, and cells with an activated alternative pathway are quiescent but resistant to the drug. We describe a dynamical process of tumour growth under various drug regimens using the explicit solution of mean-field equations.
Introduction
Despite the recent advances of targeted treatments and immunotherapy, complete cure of cancer is still rare due to the almost inevitable emergence of resistance [1, 2] . Drug resistance arises from a wide range of complex processes at multiple levels [3] [4] [5] . At the tumour level, drug response emerges primarily from population dynamics of cancer cells. The most well-known mechanism is clonal evolution [6, 7] . A bulk tumour is often populated by a heterogeneous group of cancer cells with diverse mutational landscapes, epigenomic states, pathway activities and gene regulatory programs. Treatments induce differential fitness of subclones and consequently select for the most resistant ones. In addition to clonal evolution, treatments may also induce differential plasticity of tumour cells by shifting their pathway activities [8] and regulatory programs [9] . The major difference between these two processes pertains to reversibility of drug resistance. For clonal evolution, drug sensitivity of an individual cell is determined solely by its genetic landscape and thus remains invariant during its life span. Drug resistance of a subclone is thus an irreversible phenotype as a resistant subclone will rarely back-mutate to a sensitive one.
For differential plasticity, drug sensitivity of an individual cell is a reversible dynamic state rather than a fixed phenotype. Both mechanisms are supported by numerous experimental evidence (e.g., for clonal evolution, [10] ; for differential plasticity of tumour cells [8, [11] [12] [13] [14] ).
However, the latter process may account for drug resistance that can be reverted when the therapy is lifted [15, 16] .
There is a rich literature of mathematical models for tumour clonal evolution that undergoes treatments (e.g., [17] [18] [19] [20] [21] [22] [23] ). In contrast, models of cellular plastic responses to treatments are relatively limited and recent (e.g., [24] [25] [26] , see also reviews [27] [28] [29] ). The ultimate purpose of those models is to quantitatively predict tumour's drug responses and employ this information to design effective treatments. Previously, we proposed a unified framework encompassing both mathematical models of tumour population dynamics and treatment design [30] . We considered a simple evolution model involved in subclones with differential resistance of two drugs, and tested efficacy of six heuristic treatment strategies by simulating population dynamics with a large number of parameter combinations informed by literature and clinical experience. We further extended the work by three drug systems and generalizing treatment strategies that incorporate long-term prediction of tumour population composition [31] .
An important missing piece in this unified framework is a mathematical model that tackles reversible drug responses of cancer cells. To fill this gap, here we propose a model to explore the population dynamics of cancer cells during or after treatment with targeted agents that produce reversible effects. The state of each cell is inferred from the activities of multiple inter-dependent pathways, whereas the fitness of each cell depends on its internal state and the external environment (i.e. drug dosage). Treatments alter the cellular state composition of the population by both facilitating the single-cell state transitions in certain directions and inhibiting proliferation of subpopulations with different efficiencies. To capture the essence of the considered phenomenon, we consider only a simple scenario in which there are two major populations with mutually antagonistic signalling pathways. The main pathway promotes cell proliferation more efficiently but is also sensitive to a therapeutic agent. The alternative pathway induces slow proliferation but is also resistant to the agent. Due to reversibility of the states, the treatment strategy aims to balance between controlling the tumour load and reducing the influence of resistant cells.
Despite its simplicity, this model represents reasonably well the switching behaviour of BRAF V600E mutant melanomas treated with BRAF inhibitor (vemurafenib) as previously reported [32, 33] . Melanoma is a frequently lethal form of skin cancer with incidence rates continuing to rise in many countries [34] . Approximately half of cases harbour a BRAF V600 mutation [35] . The resulting mutation leads to constitutive activation of a down-stream cascade of the mitogen activated protein (MAPK) pathway including MEK and ERK that promote proliferation of cancer cells. Treatment with single-agent BRAF inhibitor disrupts MAPK signalling and achieves remission but leads to relapse in 6.7 months on average [32] . As of 2014, the standard of care for BRAF V600 mutant melanoma is the combination of inhibitors of BRAF and MEK [36, 37] . Still, resistance emerges through numerous genetic mechanisms [38] [39] [40] [41] or phenotypic changes, such as switching from the suppressed MITF pathway to an alternative pathway involving activation of NFκB [13, 14, 42, 43] . The latter process of switching between two major oncogenic programs is accompanied by physiological changes in cancer cells [44] .
These characteristics allow us to abstract the problem and formulate a minimal dynamical model that involves interactions of two distinct pathways. We derive the master equations for the dynamics of tumour population size and state composition and find their analytic solutions with arbitrary drug regimens. Based on these solutions, we compare the performance of three treatment strategies on simulated data: i) static treatments with continuous and constant dosages,
ii) periodic treatments with regular intermittent treatment days and drug holidays, and iii) the treatments that minimize the tumour size change after fixed time periods.
Model and methods
Assumptions and concepts
We consider a general and abstract case where cancer cells are self-replicating entities possessing different internal states with different proliferative capacities, distinct sensitivities to treatments, and consequently, the size and composition of the entire tumour population. From this more general case, we study a particular instance in detail as outlined below. The following simplifying assumptions are introduced:
i. The mutational landscape of tumour cells does not acquire major driver events ("hallmarks of cancer" [45] ) or new resistance mutations during the course of therapy. In fact this may not be the case and integration of models of genetic evolution of resistance and cellular plasticity is an important future step.
ii. The dominant subclone of tumour cells, which is the focus here, by default possesses elevated activities of the "main" pathway that render it highly proliferative.
iii. Proliferation can also be sustained by an "alternative" pathway with lower efficiency. The two pathways are mutually inhibitory, thus without external intervention the tumour population is dominated by cells with an active main pathway over those with an active alternative pathway. Activities of the two pathways demarcate three cellular states (Fig 1BC) : active main pathway and inactive alternative pathway (state "1"), inactive main pathway and active alternative pathway (state "2"), and inactive main and alternative pathways (state "0").
Simultaneous activation of both pathways is not allowed since they are mutually inhibitory. 0 is a transient state between 1 and 2.
Each single cell can encounter three stochastic events: proliferation, death, and state
The population dynamics of the birth-death process can be well approximated by ordinary differential equations. To determine the population dynamics of cellular states, we adopt a well-known approach from statistical physics by treating cells as particles undergoing Brownian motions inside a double-well potential [46] . In this model, each pathway possesses a double-well potential. The two equilibria of the system (the two local minima of the potential) represent up and down regulation of the two pathway activities (Fig 1D) .
Probabilities of staying in each state (and thereby the fraction of cells in each state) are determined by the "energy gap" between two local minima. Without external intervention, lower wells (more likely states) of the main pathway correspond to up-regulation of the main pathway and down-regulation of the alternative pathway.
The drug inhibits both activity of the main pathway and proliferation of main pathwayactive cells, but has no effect on the alternative pathway. Mathematically it lifts the well of the up regulation state and lowers the well of the down regulation state of the main pathway potential function, and does not change the shape of the alternative pathway potential function. with regular intermittent treatment days and drug holidays, and an analytic strategy derived from optimal control theory.
Dynamic equations.
Population dynamics of cells follows a linear differential equation:
where ( ) n t denotes the total population size at time t, x(t) is the fraction of resistant cells (at state 
Here, the first term resembles the replicator dynamics [48] , where the growth rate is equal to the difference between two fitness costs -it describes cell competition between different types. The two following terms indicate the transition flows between the sensitive state 1 and the resistant state 2. We denote the transition rates to and from the resistant states as μ and μ respectively.
We assume a linear dependence of the drug effect on the treatment intensity σ .
Consequently, the double-well potential is defined by two quadratic polynomials that are attached to each other at the intermediate threshold point (Fig S1B) . Then the values of E -and (1)- (2) are also quadratic functions of σ , see also Appendix A for more details.
We refer readers to Table 1 for summary of all model parameter and their estimates.
Results

Static treatment.
First, we report dynamics of tumour size of static treatments where the drug is administered at a constant dosage. The treatments with low intensities (e.g. Tumour shrinkage may not predict subsequent outcomes when dynamics of heterogeneous populations are considered.
Periodic treatment.
Tumour relapse is driven by emergence of resistant cells. This process is reversible in our model (Fig S3C) , so we may expect improvement in the therapeutic outcomes by leveraging treatment and non-treatment to create a subtle balance of proliferative and resistant cells. The simplest strategy of this kind is a periodic treatment with an equal length of active phase and drug holidays. (Fig 3A) . First, the time horizon T ends with a drug holiday ( = (e.g., the blue dot in Fig 3C and the blue waveform in Fig 3B) yield the local maxima in tumour size. All treatment schedules under 0.2 σ = lead to low terminal level of resistance (Fig 3C bottom panel) , indicating they are incapable of eliminating the proliferative (sensitive) part of the tumour.
We then consider periodic treatments with a higher average intensity of 0.4 σ = (Fig 3D) .
In this setting, the outcomes of the two scenarios are the opposite of the previous setting 0.2. Fig 3D and the red waveform in Fig 3B) give rise to local maxima in tumour size (e.g., the red dot in Fig 3D and the red waveform in Fig 3B) .
The results drawn from these two cases can be summarized as a simple guideline. When the drug appears to be ineffective because only low values of average intensity can be achieved (e.g., 0.2), σ = the optimal schedule is to shorten active phases and create an integral number of complete periods, to maximize the average intensity within the active periods. This will amplify the relatively weak intensity within active phases. When the drug appears to be of more effective for pathway inhibition, because sufficiently average intensity is permitted (e.g.,
.4 0 σ = ), the optimal schedule is to distribute the drug over a longer time span and create a half integral number of complete periods, assuming this is permitted. All the other terminal phases will truncate either an active phase or a drug holiday phase and thus lead to inferior outcomes.
We further find the values of σ and Δ that jointly optimize the treatment outcome ( Fig   S4A) . This is exactly when we observe the shift in distribution of local minima and maxima for the fold increase in tumour size (Fig S4C) . Fig S4A) . This corresponds to the treatment with 22 active phases and 21 drug holidays during two years of treatment (Fig S4D) . and the fold increase is 2.81. We also obtain similar results when varying the adjusted treatment intensity σ rather than the average σ ( Fig   S6) .
Optimal treatment.
Both static and periodic treatments are straightforward to implement but often not optimal in terms of the outcome. Here we define optimality as minimizing the tumour size at a fixed terminal time (or time horizon) T. To solve this problem, we apply optimal control theory to update treatment intensities at each moment depending on the tumour state (tumour size and level of resistance). This requires a constant monitoring of the patient, see [16] for discussion. In and then switch to the maximal dosage throughout the remaining time to eradicate as many proliferative cells as possible (curves ii and iii in Fig 4; Fig 5B) . Yet when the time horizon is short, the long term benefit of a balanced population is no longer relevant, and the optimal treatment is to reduce the current tumour size by administering the maximal dosage (curve i in Fig 4; Fig 5B) . The clinically relevant time horizon may depend on other factors such as the emergence of genetically distinct subclones with different properties.
Comparison of different treatments.
The performances of the three aforementioned treatment strategies conform with the following order: best static treatment ≤ best periodic treatment ≤ optimal treatment. Superiority of periodic over static treatments is illustrated in 
Sensitivity analysis.
Eleven baseline parameter values in the model (Table 1) are not guaranteed to be accurate and unique. To investigate the influence of parameter values in optimal treatment outcomes, we assess the fold change in tumour size after two years by varying parameter values. Fig 6A shows the effect of variation in characteristic switching times between the main and alternative pathways, when the cost of resistance
The tumour does not shrink if the inverse switch from the alternative to the main pathway is slower than the direct switch from the main to the alternative pathway (the red-yellow region above the solid black line), while remission can be achieved if the reciprocal relation between the two switching times holds (the blue region below the solid black line). However, the result depends on the cost of resistance: a higher cost induces slower proliferation of resistant cells and thus accommodates a wider range of switching times leading to tumour reduction (Fig 6C) , while a lower cost has the opposite effect (Fig 6B) . We further investigate how the optimal proportion of resistant and sensitive cells depends on aforementioned parameters (Fig S7) . The optimal proportion of resistant cells is positively correlated with 1 / μ (Fig S7B) and negatively correlated with 1 / μ (Fig S7A) . We also notice that the optimal proportion is below 50% only when μ is four times slower than μ (area below dashed line in Fig S7C) . (Fig S8A) and the robustness parameter κ (Fig S8E) . The latter indicates how likely the main pathway switches between its on-and offstates due to internal stochastic effects. The system possessing the baseline κ value used in our simulation yields near the smallest tumour size (green dot in Fig S8E) . A more unstable main pathway (smaller κ values) impairs the effect of drug holidays as a sensitive cell will randomly drift to the resistant state with high probability. Reciprocally, a more stable main pathway (higher κ values) deteriorates the effect of treatment as a cell is not responsive to the pathway inhibitor. Thus time-varying treatments are effective only in a narrow range of pathway robustness.
Discussion
Both optimal and periodic treatments outperform the static treatment by more than two folds in terms of the tumour size after two years (2.52-fold, 2.93-fold and 4.85-fold respectively).
Efficacy of periodic treatments was discussed in prior studies [16, 52] . Drug addiction is one possible cause [33] : resistant subclones not only tolerate the administered drug but also depend on it. Drug holidays in these cases deplete the "nutrient" supply and reduce the resistant subclone population. Gatenby et al. [53] considered a more general "adaptive therapy" as means to maintain proper balance of sensitive and resistant subclone populations undergoing competition.
Our simulation outcomes corroborate the superiority of periodic treatments and concur with the prior discussions about their benefits, albeit the proposed mechanisms causing the benefits are different. Those mechanisms may co-exist and can be all tackled by periodic treatments, at least in the setting of a single therapy as modelled here. In spite of a good approximation to the global optimum and simplicity of implementation, the best periodic treatment is still marginally inferior to the optimal treatment strategy. In principle, one should always adopt the treatment strategy that yields the best outcome. In practice, physicians have to consider multiple factors when deciding the treatment including cost-effectiveness, the higher risk of medical errors when implementing complex recommendations, and the feasibility of repeated tumour sampling or liquid biopsy to provide accurate input data to correctly design and execute an optimal control algorithm. Both periodic and optimal treatments likely require substantial modifications.
Traditionally in clinical studies the current agent is abandoned when there is a 20% increase in the sum of the longest linear dimension of large measurable lesions, corresponding to a 73% increase in volume [54] . Such a practice does not allow for periodic treatments. Also, the optimal treatment in our model requires continuous monitoring of the tumour population composition. If such monitoring is either costly or infeasible, then a properly designed periodic treatment is a reasonable surrogate for the optimal treatment. Dynamic treatments of cancer require biomarkers for functional states that can be continuously and non-invasively monitored. This may be a greater challenge for complex gene expression changes and their associated physiological changes than it is for mutations for which highly sensitive polymerase chain reaction techniques are available.
Intriguingly, the best treatment plans of all three strategies attempt to establish and maintain an optimal proportion of sensitive and resistant cells (fraction of sensitive cells is about 75% in our simulations) throughout the entire period (Fig 5B) . The best static treatment drives the population toward a value above such optimal composition. The best periodic treatment quickly leads the population to the optimal composition and then makes it oscillate around this value. The global optimal treatment quickly forces the population toward the optimal composition, alters the dosage to maintain it, and finally maximizes the dosage for final most efficient curbing of the tumour at the very end. The outcome of a treatment strategy seems to depend critically on its controllability to reach this composition as quick as possible and stay there as long as possible. In this sense, the static treatment is a poor controller, because it cannot reach that target. Both periodic and optimal treatments are good controllers as they quickly reach the target value and maintain it onward. Curiously, while the total population under the best periodic treatment steadily increases with small ripples, the total population under the optimal treatment grows more rapidly and finally plunges to a much lower value (Fig 5A) . This is because the higher growth rate allowed by the optimal treatment leads to a more optimal balance of sensitive and resistant cells for efficient final curbing of the tumour. This also identifies a possible hurdle in implementing an optimal treatment regimen into clinical practice because its performance at the initial state is even worse than with a static treatment, and this is likely to result in earlier termination of the therapy per current paradigms (Fig 5A) . However, design of optimal treatment may help to estimate performance of other suboptimal treatments such as periodic or adaptive regimens. Thus, the solution of optimal control problems for tumour management may contribute valuable information even if not applied in practice.
Many of the parameter estimates such as the characteristic time of switching between two genetic programs are subjected to uncertainty. Despite impressive progress in the field, recent studies [8, 14] indicated that the technology of single-cell transcriptomics still does not allow rigorous measurement of the kinetics of a change in growth rates of sensitive and resistant cells due to epigenetic reprogramming. Laboratory studies in cell lines may not reflect observations of net growth rates of tumours in patients (cf reported proliferation rates in [13] and [55] ). This causes difficulties for model inference. Based on this, we first proposed an estimate of characteristic switching times and then implemented a sensitive analysis to verify the robustness of our outcomes. We anticipate in the future that laboratory model systems will be developed that enable testing and refinement of our findings.
We assume that reprogrammable cell states require not only an instant change in activity of both pathways (with faster time scales), but also its "hardwiring" in the physiology of a cell [25] . For example, a recent study [8] implements a special state called a meta-resistant state that still does not guarantee a permanent resistant state, but remains reversible, similar to our model formulation (cf Fig 1B and C) . 
